Interesting paper by the groups of Jing Yang and Ping Xu in Journal of Proteome Research. They directly compared five different cleavable biotin tags and 3 different workflows to characterize their performance in residue-specific chemoproteomics. doi.org/10.1021/acs.jp…

One week until our free #RSCDesktopSeminar Lectureship webinar, featuring our 2021 & 2022 winners, Dr Jacob Bush (Jacob Bush) and Dr Nir London (London Lab)! ✨ 📅 4 August 2022 at 1 PM BST 🔗 bit.ly/3NZlt8j

Register now for our free #RSCDesktopSeminar Lectureship webinar, featuring Lectureship winners Jacob Bush & London Lab! 📅 4 Aug 2022 at 1 PM BST Even if you can't attend on the day, be sure to register to receive a recording of the webinar later! rsc.zoom.us/webinar/regist…

Our #RSCDesktopSeminar Lectureship is TODAY! 🎉 Register now to see talks by our Lectureship winners, Dr Jacob Bush (Jacob Bush) and Dr Nir London (London Lab) at 1 PM BST ➡ rsc.zoom.us/webinar/regist…

We're recruiting for the Crick/GSK EPSRC prosperity partnership! If you're thinking about a postdoctoral position have a look at the link below! The Francis Crick Institute crick.ac.uk/careers-study/…

Great opportunity to join the The Francis Crick Institute / GSK partnership to build systems chemical biology approaches to therapeutic discovery. #chemicalbiology #chembio #covalentmodifiers

Excited to share this opportunity for a bioinformatics post doc in the Crick-GSK collaboration linkedin.com/posts/activity…

Check out Arron Aatkar’s work taking reactive fragments into new landscapes: beyond-cysteine covalent ligand discovery with sulfonyl fluorides ChemRxiv. Great collab GSK, Chemistry - University of Strathclyde, The Francis Crick Institute. #chemicalbiology #covalentmodifiers (Artwork Emma Grant) lnkd.in/eec64JRZ

Efficient Ligand Discovery Using Sulfur(VI) Fluoride Reactive Fragments [Arron Aatkar] dlvr.it/SfJZpN

Our latest paper in collaboration with GSK describes how the reactivity of a series of SuFEx reagents influences covalent modificaiton of the proteome. Congratulations to Katharine Gilbert , Jacob Bush and Arron Aatkar . pubs.acs.org/doi/10.1021/ac…

Excited to share the latest publication from our collaboration between GSK and The Francis Crick Institute. Expanding the liganded DUBome to support target validation in biomedical research. Great work from Rosa Cookson, Aini Vuorinen and co-authors. #chembio Target 2035 biorxiv.org/content/10.110…

Check out recent work by Jacob Bush, Nicholas Tomkinson & co: 'Reactive fragments targeting carboxylate residues employing direct to biology, high-throughput chemistry' The #OpenAccess article is online now🔓 pubs.rsc.org/en/content/art… 📍 GSK and University of Strathclyde

Happy to share our latest preprint. Catherine used #biochemical & #structural methods to study the #epigenetic reader protein BDF5 as a potential drug target in #Leishmania. Partnership between Jeremy Mottram , Wilkinson lab YSBL & Stuart Conway. biorxiv.org/cgi/content/sh…

Our 'Mutate and Conjugate' paper is out now in ACS Chem Biol (ACS Publications Bio & Med Chem Content)! We combine site-directed mutagenesis and electrophilic fragments to identify inhibitors the mutant protein with a view to helping target validation. pubs.acs.org/doi/10.1021/ac… #chembiol #medchem

Hot off the press! Check out our ‘mutate and conjugate’ paper in ACS Publications Bio & Med Chem Content 🔥 Here we demonstrate that combining site-directed mutagenesis and reactive fragments can be used to rapidly identify selective covalent probes for target validation studies.

I'm delighted to share our recent article developing an approach to identify cyclic peptide binders of challenging protein targets directly in cell lysates - led by Catherine Hurd with GSK's Jacob Bush and Andy Powell The Crick IMPCH Oficial

Fantastic work by George, Emma and the team in the GSK and The Francis Crick Institute collaboration: a robust chemoproteomics platform to screen covalent compounds against the proteome. Exciting work on-going to deploy at scale with AI/ML to map the druggable proteome. biorxiv.org/content/10.110…

Rapid optimisation of covalent and non-covalent SARS MPro inhibitors by ‘direct-to-biology’ reactive fragment screening. Great work by Harry Wilders on ChemRxiv from GSK, University of Strathclyde and The Francis Crick Institute. #chembio chemrxiv.org/engage/chemrxi…

Excited to share a key part of my postdoctoral work from The Francis Crick Institute and GSK , published in Nature Communications . A collaborative project to develop a high-throughput chemoproteomics platform for profiling cysteine-reactive fragments in native biological systems. nature.com/articles/s4146…

Synthesis without purification still yields clear fragment hits.  'Direct-to-Biology' screens crude reaction mixtures & yields covalent and noncovalent inhibitors of SARS-CoV-2 main protease practicalfragments.blogspot.com/2025/03/crude-… Angewandte Chemie Jacob Bush GSK